A Phase 3 interventional study of Ramucirumab and Placebo in Metastatic Non-Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Active, not recruiting at 106 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 9 under way, 2 of them phase 3. Ramucirumab · Carcinoma, Non-Small-Cell Lung.
Among the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, this one is the 3rd largest by enrollment, is one of 2 that started in 2015, is one of 3 in phase 3, and was the 7th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →2 of the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
SWOG Cancer Research Network · Sites in United States
Ages 18 min+
By country, each count listing its studies:
Ramucirumab: first FDA approval 2014 (CYRAMZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 17 · Phase 3 3
First in 2009; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 545 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 74 across the 24 interventional studies. Of the 14 that completed or were terminated, 13 (93%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 24 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 18th largest by enrollment of the 139 interventional ones that give a count, is one of 9 that started in 2015, is one of 25 in phase 3, reaches primary completion later than 1 of the 19 other live ones, and was the 109th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
2 of the studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03527108Fox Chase Cancer CenterNivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | 2026-12 |
| NCT03909334Xiuning LeStudy of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the efficacy and safety of ramucirumab in combination with erlotinib as compared to placebo in combination with erlotinib in previously untreated participants with stage IV non-small cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation (Exon 19-Del and Exon 21 L858R). Safety and tolerability of ramucirumab in combination with erlotinib will be assessed in Part A before proceeding to Part B.
The purpose of Part C is to determine the efficacy and safety of ramucirumab in combination with gefitinib in previously untreated East Asian participants with EGFR mutation-positive metastatic NSCLC and of ramucirumab in combination with osimertinib in those participants whose disease progressed on ramucirumab and gefitinib and that have T790M - positive metastatic NSCLC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A: 10 milligrams per kilogram (mg/kg) ramucirumab administered every 2 weeks intravenously (IV) in combination with 150 mg erlotinib daily orally. Participants may continue to receive treatment until discontinuation criteria are met. Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally. Participants may continue to receive treatment until discontinuation criteria are met.
Drug: Ramucirumab · Drug: Erlotinib
Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally. Participants may continue to receive treatment until discontinuation criteria are met.
Drug: Placebo · Drug: Erlotinib
Part C: 10 mg/kg ramucirumab administered every 2 weeks intravenously (IV) + 250 mg Gefitinib or 80 mg Osimertinib daily orally. * Ramucirumab and gefitinib administered during period 1. * Ramucirumab and osimertinib administered during period 2.
Drug: Ramucirumab · Drug: Gefitinib · Drug: Osimertinib
Administered IV.
Also known as: LY3009806
Administered IV.
Administered orally.
Administered orally.
Administered orally.
Part B: Progression Free Survival (PFS)
PFS is defined as the time from the date of randomization to the date of radiographically documented progressive disease (PD) based on investigator assessment, or the date of death due to any cause, whichever is first assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.
Time frame: Randomization to Measured Progressive Disease or Death from Any Cause (Up To 37 Months)
Number of Participants With Treatment-Emergent Adverse Events
A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.
Time frame: Cycle 1 Day 1 through End of Study (Up To 3 Years)
Part B: Overall Survival (OS)
OS was defined as the time from the date of randomization to the date of death from any cause. For each participant who was not known to have died as of the data-inclusion cutoff date for a particular analysis,OS was censored for that analysis at the date of last contact prior to the data-inclusion cutoff date (contacts considered in the determination of last contact date include adverse event (AE) date, lesion assessment date, visit date, and last known alive date).
Time frame: Randomization to Date of Death from Any Cause (Up To 37 Months)
Part B: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])
ORR was defined as the percentage of randomized participants achieving a best overall response of partial response (PR) or complete response (CR) assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as the disappearance of all lesions, pathological lymph node reduction in short axis to \<10 mm, and normalization of tumor marker levels of non-target lesions. PR was at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.
Time frame: Randomization to Progressive Disease (Up To 37 Months)
Part B: Percentage of Participants With CR, PR, or Stable Disease (SD) (Disease Control Rate [DCR])
DCR was defined as the percentage of randomized participants achieving a best overall response of CR,PR, or stable disease(SD) assessed via Response Evaluation Criteria in Solid Tumors(RECIST) version 1.1. CR was defined as the disappearance of all lesions,pathological lymph node reduction in short axis to \<10 mm, and normalization of tumor marker levels of non-target lesions.PR was at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters.SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease(PD) was at least a 20% increase in the sum of the diameters of target lesions,taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.The appearance of 1 or more new lesions is also considered progression.
Time frame: Randomization to Progressive Disease (Up To 37 Months)
Part B: Duration of Response (DoR)
DoR was defined as the date of first documented CR or PR (responder) to the date of progressive disease or the date of death due to any cause, whichever was earlier. If a responder was not known to have died or have progressive disease, then the participant was censored at the date of last evaluable tumor assessment.CR was defined as the disappearance of all lesions, pathological lymph node reduction in short axis to \<10 mm, and normalization of tumor marker levels of non-target lesions. PR was at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.
Time frame: Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression or Death Due to Any Cause (Up To 37 Months)
Part B: Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab
Part B: Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab
Time frame: Cycle 2 Day 1: Predose; Cycle 4 Day 1: Predose; Cycle 7 Day 1: Predose; Cycle 14 Day 1
Part B: Number of Participants With Anti-Ramucirumab Antibodies
Part B: Number of Participants With Anti-Ramucirumab Antibodies.
Time frame: Cycle 1 Predose through Follow-up (Up To 37 Months)
Part B: Best Change From Baseline on the Lung Cancer Symptom Scale (LCSS)
The LCSS consisted of 9 items: 6 items focused on lung cancer symptoms \[loss of appetite, fatigue, cough, dyspnea (shortness of breath), hemoptysis (blood in sputum), and pain\] and 3 global items (symptom distress, interference with activity level, and global quality of life). Participant responses to each item were measured using visual analogue scales (VAS) with 100-millimeter (mm) lines. A higher score for any item represented a higher level of symptoms/problems. The LCSS total score was defined as the mean of all 9 items. Average symptom burden index (ASBI) was calculated as the mean of the six symptom-specific questions from the LCSS. Potential scores range from 0 (for best outcome) to 100 (for worst outcome).
Time frame: Baseline, End of Study (Up To 37 Months)
Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score
The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It consists of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, and extreme problems/unable to), ranging from 1 to 5 (good to bad). Dimension responses were converted to an index score using UK weights. The index scores were anchored on full health (1.0) to dead (0) with negative values assigned to health states considered worse than death.
Time frame: Baseline, Cycle 10 (each cycle is 2 weeks)
Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score
The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It consists of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, and extreme problems/unable to), ranging from 1 to 5 (good to bad). Dimension responses were converted to an index score using UK weights. The index scores were anchored on full health (1.0) to dead (0) with negative values assigned to health states considered worse than death.
Time frame: Baseline, Cycle 28 (each cycle is 2 weeks)
Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score
The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It consists of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, and extreme problems/unable to), ranging from 1 to 5 (good to bad). Dimension responses were converted to an index score using UK weights. The index scores were anchored on full health (1.0) to dead (0) with negative values assigned to health states considered worse than death.
Time frame: Baseline, Cycle 40 (each cycle is 2 weeks)
| Milestone | Part A: Ramucirumab + Erlotinib | Part B: Ramucirumab+ Erlotinib | Part B: Placebo+ Erlotinib |
|---|---|---|---|
| Started | 14 | 224 | 225 |
| Received at least one dose of study drug | 14 | 221 | 225 |
| Completed | 10 | 141 | 173 |
| Not completed | 4 | 83 | 52 |
| Withdrew: Withdrawal by subject | 1 | 14 | 9 |
| Withdrew: Other | 0 | 2 | 0 |
| Withdrew: Did not receive study treatment | 0 | 3 | 0 |
| Withdrew: Alive on study treatment | 3 | 64 | 43 |
PFS is defined as the time from the date of randomization to the date of radiographically documented progressive disease (PD) based on investigator assessment, or the date of death due to any cause, whichever is first assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.
| Months | Part B: Ramucirumab+ Erlotinib | Part B: Placebo+ Erlotinib |
|---|---|---|
| Part B: Progression Free Survival (PFS) | 19.4 (15.4 to 21.6) | 12.4 (11.0 to 13.5) |
A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.
| Participants | Part A: Ramucirumab + Erlotinib | Part B: Ramucirumab + Erlotinib | Part B: Placebo + Erlotinib |
|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events | 14 | 221 | 225 |
OS was defined as the time from the date of randomization to the date of death from any cause. For each participant who was not known to have died as of the data-inclusion cutoff date for a particular analysis,OS was censored for that analysis at the date of last contact prior to the data-inclusion cutoff date (contacts considered in the determination of last contact date include adverse event (AE) date, lesion assessment date, visit date, and last known alive date).
| months | Part B: Ramucirumab+ Erlotinib | Part B: Placebo+ Erlotinib |
|---|---|---|
| Part B: Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
ORR was defined as the percentage of randomized participants achieving a best overall response of partial response (PR) or complete response (CR) assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as the disappearance of all lesions, pathological lymph node reduction in short axis to \<10 mm, and normalization of tumor marker levels of non-target lesions. PR was at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.
| percentage of participants | Part B: Ramucirumab+ Erlotinib | Part B: Placebo+ Erlotinib |
|---|---|---|
| Part B: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) | 76.3 (70.8 to 81.9) | 74.7 (69.0 to 80.3) |
DCR was defined as the percentage of randomized participants achieving a best overall response of CR,PR, or stable disease(SD) assessed via Response Evaluation Criteria in Solid Tumors(RECIST) version 1.1. CR was defined as the disappearance of all lesions,pathological lymph node reduction in short axis to \<10 mm, and normalization of tumor marker levels of non-target lesions.PR was at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters.SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease(PD) was at least a 20% increase in the sum of the diameters of target lesions,taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.The appearance of 1 or more new lesions is also considered progression.
| percentage of participants | Part B: Ramucirumab+ Erlotinib | Part B: Placebo+ Erlotinib |
|---|---|---|
| Part B: Percentage of Participants With CR, PR, or Stable Disease (SD) (Disease Control Rate [DCR]) | 95.1 (92.3 to 97.9) | 95.6 (92.9 to 98.2) |
DoR was defined as the date of first documented CR or PR (responder) to the date of progressive disease or the date of death due to any cause, whichever was earlier. If a responder was not known to have died or have progressive disease, then the participant was censored at the date of last evaluable tumor assessment.CR was defined as the disappearance of all lesions, pathological lymph node reduction in short axis to \<10 mm, and normalization of tumor marker levels of non-target lesions. PR was at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.
| months | Part B: Ramucirumab+ Erlotinib | Part B: Placebo+ Erlotinib |
|---|---|---|
| Part B: Duration of Response (DoR) | 18.0 (13.9 to 19.8) | 11.1 (9.7 to 12.3) |
Part B: Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab
| microgram per milliliter (µg/mL) | Part B: Ramucirumab+ Erlotinib |
|---|---|
| Cycle 2 | 39.6 ± 32 |
| Cycle 4 | 68.5 ± 37 |
| Cycle 7 | 85.7 ± 32 |
| Cycle 14 | 99.4 ± 31 |
Part B: Number of Participants With Anti-Ramucirumab Antibodies.
| Participants | Part B: Ramucirumab+ Erlotinib | Part B: Placebo+ Erlotinib |
|---|---|---|
| Part B: Number of Participants With Anti-Ramucirumab Antibodies | 14 | 18 |
The LCSS consisted of 9 items: 6 items focused on lung cancer symptoms \[loss of appetite, fatigue, cough, dyspnea (shortness of breath), hemoptysis (blood in sputum), and pain\] and 3 global items (symptom distress, interference with activity level, and global quality of life). Participant responses to each item were measured using visual analogue scales (VAS) with 100-millimeter (mm) lines. A higher score for any item represented a higher level of symptoms/problems. The LCSS total score was defined as the mean of all 9 items. Average symptom burden index (ASBI) was calculated as the mean of the six symptom-specific questions from the LCSS. Potential scores range from 0 (for best outcome) to 100 (for worst outcome).
| millimeter | Part B: Ramucirumab+ Erlotinib | Part B: Placebo+ Erlotinib |
|---|---|---|
| Loss of Appetite | -17.07 ± 0.92 | -18.16 ± 0.91 |
| Fatigue | -19.35 ± 0.91 | -19.45 ± 0.90 |
| Cough | -21.22 ± 0.58 | -22.09 ± 0.57 |
| Shortness of Breath | -14.46 ± 0.57 | -15.93 ± 0.57 |
| Blood in Sputum | -1.58 ± 0.25 | -1.94 ± 0.25 |
| Pain | -13.57 ± 0.59 | -14.69 ± 0.59 |
| Symptom distress | -15.91 ± 0.67 | -16.15 ± 0.67 |
| Interference with Activity Level | -14.43 ± 0.83 | -15.60 ± 0.82 |
| Global Quality of Life | -16.21 ± 0.95 | -18.12 ± 0.94 |
| Average Symptom Burden Index | -12.17 ± 0.57 | -13.05 ± 0.57 |
| Total LCSS | -12.00 ± 0.62 | -12.71 ± 0.61 |
The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It consists of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, and extreme problems/unable to), ranging from 1 to 5 (good to bad). Dimension responses were converted to an index score using UK weights. The index scores were anchored on full health (1.0) to dead (0) with negative values assigned to health states considered worse than death.
| score on a scale | Part B: Ramucirumab+ Erlotinib | Part B: Placebo+ Erlotinib |
|---|---|---|
| Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score | 0.02 ± 0.15 | 0.02 ± 0.15 |
The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It consists of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, and extreme problems/unable to), ranging from 1 to 5 (good to bad). Dimension responses were converted to an index score using UK weights. The index scores were anchored on full health (1.0) to dead (0) with negative values assigned to health states considered worse than death.
| score on a scale | Part B: Ramucirumab+ Erlotinib | Part B: Placebo+ Erlotinib |
|---|---|---|
| Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score | 0.02 ± 0.18 | 0.01 ± 0.1 |
The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It consists of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, and extreme problems/unable to), ranging from 1 to 5 (good to bad). Dimension responses were converted to an index score using UK weights. The index scores were anchored on full health (1.0) to dead (0) with negative values assigned to health states considered worse than death.
| score on a scale | Part B: Ramucirumab+ Erlotinib | Part B: Placebo+ Erlotinib |
|---|---|---|
| Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score | 0.01 ± 0.15 | -0.01 ± 0.14 |
Collected over Up To 3 Years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Ramucirumab + Erlotinib | 2/14 (14.3%) | 0/14 (0%) | 14/14 (100%) |
| Part B: Ramucirumab + Erlotinib | 37/224 (16.5%) | 65/221 (29.4%) | 220/221 (99.5%) |
| Part B: Placebo + Erlotinib | 42/225 (18.7%) | 47/225 (20.9%) | 225/225 (100%) |
| Event | Part A: Ramucirumab + Erlotinib | Part B: Ramucirumab + Erlotinib | Part B: Placebo + Erlotinib |
|---|---|---|---|
| PneumoniaInfections and infestations | 0/14 | 7/221 | 1/225 |
| CellulitisInfections and infestations | 0/14 | 4/221 | 0/225 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/14 | 4/221 | 3/225 |
| PyrexiaGeneral disorders | 0/14 | 3/221 | 4/225 |
| DiarrhoeaGastrointestinal disorders | 0/14 | 3/221 | 1/225 |
| Hepatic function abnormalHepatobiliary disorders | 0/14 | 3/221 | 2/225 |
| Decreased appetiteMetabolism and nutrition disorders | 0/14 | 3/221 | 0/225 |
| Small intestinal haemorrhageGastrointestinal disorders | 0/14 | 2/221 | 0/225 |
| VomitingGastrointestinal disorders | 0/14 | 2/221 | 1/225 |
| Skin infectionInfections and infestations | 0/14 | 2/221 | 0/225 |
| Event | Part A: Ramucirumab + Erlotinib | Part B: Ramucirumab + Erlotinib | Part B: Placebo + Erlotinib |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 13/14 | 154/221 | 160/225 |
| ParonychiaInfections and infestations | 10/14 | 118/221 | 114/225 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 9/14 | 149/221 | 153/225 |
| Dry skinSkin and subcutaneous tissue disorders | 9/14 | 83/221 | 91/225 |
| Alanine aminotransferase increasedInvestigations | 7/14 | 93/221 | 70/225 |
| HeadacheNervous system disorders | 7/14 | 33/221 | 16/225 |
| HypertensionVascular disorders | 7/14 | 100/221 | 27/225 |
| StomatitisGastrointestinal disorders | 6/14 | 92/221 | 82/225 |
| AlopeciaSkin and subcutaneous tissue disorders | 6/14 | 75/221 | 44/225 |
| Aspartate aminotransferase increasedInvestigations | 5/14 | 92/221 | 58/225 |
All enrolled participants. Part C data will be reported after study completion.
| Age, Continuous(years) | Part A: Ramucirumab + Erlotinib | Part B: Ramucirumab+ Erlotinib | Part B: Placebo+ Erlotinib | Total |
|---|---|---|---|---|
| Part A | 67.6 ± 13.2 | NA ± NA | NA ± NA | 67.6 ± 13 |
| Part B | NA ± NA | 63.7 ± 10.2 | 62.9 ± 10.6 | 63.3 ± 10.4 |
| Sex: Female, Male(Participants) | Part A: Ramucirumab + Erlotinib | Part B: Ramucirumab+ Erlotinib | Part B: Placebo+ Erlotinib | Total |
|---|---|---|---|---|
| Female | 11 | 141 | 142 | 294 |
| Male | 3 | 83 | 83 | 169 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Ramucirumab + Erlotinib | Part B: Ramucirumab+ Erlotinib | Part B: Placebo+ Erlotinib | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 13 | 10 | 23 |
| Not Hispanic or Latino | 1 | 150 | 160 | 311 |
| Unknown or Not Reported | 13 | 61 | 55 | 129 |
| Race (NIH/OMB)(Participants) | Part A: Ramucirumab + Erlotinib | Part B: Ramucirumab+ Erlotinib | Part B: Placebo+ Erlotinib | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 7 | 172 | 174 | 353 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 |
| White | 7 | 52 | 48 | 107 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Part A: Ramucirumab + Erlotinib | Part B: Ramucirumab+ Erlotinib | Part B: Placebo+ Erlotinib | Total |
|---|---|---|---|---|
| Romania | 0 | 2 | 0 | 2 |
| Hong Kong | 0 | 9 | 6 | 15 |
| United States | 0 | 7 | 2 | 9 |
| Japan | 7 | 106 | 105 | 218 |
| United Kingdom | 0 | 4 | 3 | 7 |
| Spain | 7 | 23 | 19 | 49 |
| Canada | 0 | 0 | 2 | 2 |
| South Korea | 0 | 25 | 29 | 54 |
| Turkey | 0 | 3 | 4 | 7 |
| Taiwan | 0 | 26 | 30 | 56 |
| Italy | 0 | 8 | 12 | 20 |
| France | 0 | 4 | 7 | 11 |
| Germany | 0 | 7 | 6 | 13 |
| Geographic Region(Participants) | Part A: Ramucirumab + Erlotinib | Part B: Ramucirumab+ Erlotinib | Part B: Placebo+ Erlotinib | Total |
|---|---|---|---|---|
| East Asia | 7 | 166 | 170 | 343 |
| Other* | 7 | 58 | 55 | 120 |
Showing the first 100 of 106 sites across 14 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from May 2015 to primary completion in Jan 2019, 44 months.
Results were first posted in Mar 2020, 1 year 1 month after primary completion.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 44 months is above that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ramucirumab · Erlotinib · Osimertinib
Carcinoma, Non-Small-Cell Lung →